Mimedx Group Inc (MDXG) 8.65 $MDXG
MiMedx Announces Release Date For 2014 Full Year Results
PR Newswire - Wed Feb 04, 7:52AM CST
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today that its results for the fourth quarter and year ended December 31, 2014, will be released before the opening of the market on Thursday, February 26, 2015. MiMedx will host a live broadcast of its fourth quarter and year-end conference call on Thursday, February 26, 2015, at 10:30 a.m. EST. A listen-only simulcast of the MiMedx conference call will be available online at the Company's website, www.mimedx.com. A 30-day online replay will be available approximately one hour following the conclusion of the live broadcast. The replay can also be found on the Company's website at www.mimedx.com.
MDXG: 8.65 (+0.23)
Organogenesis Announces MiMedx Has Dismissed its Frivolous Lawsuit
PR Newswire - Wed Feb 04, 7:00AM CST
Organogenesis Inc., a world leading regenerative medicine company, announced today that MiMedx Group, Inc. (NASDAQ: MDXG) has dismissed its lawsuit against the company, a mere month after it was announced.
MDXG: 8.65 (+0.23)
The Shuman Law Firm Investigates MiMedx Group, Inc.
Business Wire - Tue Feb 03, 7:00PM CST
The Shuman Law Firm announces that it is investigating potential claims against certain officers and directors of MiMedx Group, Inc. ("MiMedx" or the "Company"
(Nasdaq: MDXG). MiMedx is a Georgia-based company that designs, manufactures, and markets products and tissue processing services in the United States.
MDXG: 8.65 (+0.23)
INVESTOR ALERT: Investigation on Behalf of Investors of MiMedx Group, Inc. Announced by Law Offices of Howard G. Smith
Business Wire - Tue Feb 03, 5:32PM CST
Law Offices of Howard G. Smith announces that it is investigating potential claims on behalf of investors of MiMedx Group, Inc. ("MiMedx Group" or the "Company" (NASDAQ:MDXG) concerning possible violations of federal securities laws. MiMedx Group designs, manufactures and markets tissue processing products and services in the United States. Long-term shareholders of MiMedx Group are encouraged to contact the firm for more information
MDXG: 8.65 (+0.23)
MiMedx Withdraws Complaint Against Organogenesis Without Prejudice To Focus On Investigation
PR Newswire - Tue Feb 03, 8:00AM CST
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced that it has voluntarily withdrawn its tortious interference lawsuit against Organogenesis, Inc., without prejudice. MiMedx has expressly reserved all of its rights and remedies to pursue any and all claims against Organogenesis in the future, including those that were brought in the Company's original complaint.
MDXG: 8.65 (+0.23)
MIMEDX GROUP, INC. FRAUD ALERT -- Andrews & Springer LLC Announces That a Securities Fraud Class Action Has Been Filed by a Law Firm Against MiMedx Group, Inc. - MDXG
GlobeNewswire - Mon Jan 26, 7:23AM CST
Andrews & Springer LLC, a boutique securities class action law firm focused on representing shareholders nationwide, announced today that a securities fraud class action lawsuit has been filed on behalf of investors of MiMedx Group, Inc. (Nasdaq:MDXG) ("MiMedx Group" or the "Company" for possible corporate misconduct and violations of securities laws.
MDXG: 8.65 (+0.23)
Robbins Arroyo LLP Is Investigating the Officers and Directors of MiMedx Group, Inc. (MDXG) on Behalf of Shareholders
PR Newswire - Thu Jan 22, 12:45PM CST
Shareholder rights law firm Robbins Arroyo LLP is investigating whether certain officers and directors of MiMedx Group, Inc. (NASDAQCM: MDXG) breached their fiduciary duties to shareholders. MiMedx designs, manufactures, and markets products and tissue processing services in the United States.
MDXG: 8.65 (+0.23)
Lifshitz & Miller Law Firm Announces Investigation of ChannelAdvisor Corp., eHealth, Inc., InvenSense, Inc., MiMedx Group, Inc., MWI Veterinary Supply, Inc. and Xoom Corporation
PR Newswire - Thu Jan 15, 1:36PM CST
ChannelAdvisor Corp.
MWIV: 189.72 (-0.17), ECOM: 9.69 (+0.63), INVN: 16.08 (+0.09), MDXG: 8.65 (+0.23), XOOM: 15.77 (+0.64), EHTH: 10.91 (-0.04)
MiMedx Announces over 30 National Account Contracts
PR Newswire - Mon Jan 12, 7:45AM CST
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today that the status of the Company's National Account contracts with Group Purchasing Organizations ("GPOs" and Integrated Delivery Networks ("IDNs" represent in excess of 4,000 U.S hospitals under contract for MiMedx allografts.
MDXG: 8.65 (+0.23)
MiMedx Exceeds Fourth Quarter And Full Year 2014 Revenue Forecasts
PR Newswire - Mon Jan 12, 7:15AM CST
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today its record results for the fourth quarter and full year 2014, and reaffirmed its previous guidance for 2015.
MDXG: 8.65 (+0.23)
Schubert Jonckheer & Kolbe LLP Launches Investigation into Alleged Breaches of Fiduciary Duty by MiMedx Group, Inc.'s Board and Officers
PR Newswire - Fri Jan 09, 10:00AM CST
Shareholder and consumer rights law firm Schubert Jonckheer & Kolbe LLP has launched an investigation into whether certain officers and directors of MiMedx Group, Inc. (NASDAQ: MDXG) breached their fiduciary duties to MiMedx and its shareholders.
MDXG: 8.65 (+0.23)
MiMedx Group, Inc. Investors Encouraged to Contact Securities Law Firm about Investigation into Allegations of Corporate Wrongdoing
PR Newswire - Thu Jan 08, 12:13PM CST
Securities lawyers at Dunnam & Dunnam are investigating allegations for MiMedx Group, Inc. shareholders (NASDAQ: MDXG). Concerned MDXG investors who purchased between February 26, 2014 and December 31, 2014 are encouraged to contact securities attorney Hamilton Lindley by clicking here.
MDXG: 8.65 (+0.23)
MiMedx's board announces increase of USD10m in stock repurchase plan
M2 - Wed Jan 07, 5:45AM CST
Regenerative medicine company MiMedx Group (NasdaqCM:MDXG) said on Tuesday that its board of directors has increased its share repurchase plan from USD10m to USD20m.
MDXG: 8.65 (+0.23)
Law Firm Kirby McInerney LLP Investigating Potential Claims on Behalf of MiMedx Group, Inc. Stockholders
Business Wire - Tue Jan 06, 5:58PM CST
Kirby McInerney LLP is investigating potential claims against the Board of Directors of MiMedx Group, Inc. ("MiMedx" or the "Company" (Nasdaq:MDXG) concerning the government investigation into the Company's sales and marketing activities.
MDXG: 8.65 (+0.23)
MiMedx Announces $10 Million Increase to Stock Repurchase Program
PR Newswire - Tue Jan 06, 10:35AM CST
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today its Board of Directors increased the Company's authorization for its share repurchase plan from $10,000,000 to $20,000,000. The $20,000,000 authorization announced today amends the $10,000,000 authorization approved in May 2014.
MDXG: 8.65 (+0.23)
Investor Alert: Investigation into MiMedx Group Inc. Announced by Holzer & Holzer, LLC
Business Wire - Tue Jan 06, 10:34AM CST
Holzer & Holzer, LLC is investigating whether MiMedx Group, Inc. ("MiMedx" or the "Company" (NASDAQ: MDXG) and/or certain of its officers complied with the federal securities laws in making public statements regarding its business and operations. On December 31, 2014, MiMedx announced it received a subpoena from the Office of Inspector General of the Department of Health and Human Services relating primarily to a civil investigation into the Company's sales and marketing activities. The price of MiMedx stock has fallen dramatically following the announcement.
MDXG: 8.65 (+0.23)
MiMedx - A Contrarian Viewpoint
Trader Junky - at Seeking Alpha - Tue Jan 06, 10:12AM CST
MDXG: 8.65 (+0.23)
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of MiMedx Group, Inc.
PR Newswire - Mon Jan 05, 3:25PM CST
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of MiMedx Group, Inc. ("MiMedx" or the "Company" (NasdaqCM: MDXG -News). Such investors are advised to contact Peretz Bronstein or his investor relations coordinator Eitan Kimelman at info@bgandg.com or 212-697-6484.
MDXG: 8.65 (+0.23)
Can MiMedx (MDXG) Double Despite FDA Investigation? - Video Blog
David Bartosiak - Zacks Investment Research - Mon Jan 05, 1:44PM CST
Momentum Strategist David Bartosiak discusses MiMedx (MDXG) and the FDA investigation.
MDXG: 8.65 (+0.23)
INVESTOR ALERT: Investigation of MiMedx Group, Inc. Announced by Glancy Binkow & Goldberg LLP
Business Wire - Mon Jan 05, 12:58PM CST
Glancy Binkow & Goldberg LLP announces that it is investigating potential claims on behalf of investors of MiMedx Group, Inc. ("MiMedx Group" or the "Company" (NASDAQ:MDXG) concerning possible violations of federal securities laws. The investigation is focused on the Company's business and operations.
MDXG: 8.65 (+0.23)
MiMedx Announces Release Date For 2014 Full Year Results
PR Newswire - Wed Feb 04, 7:52AM CST
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today that its results for the fourth quarter and year ended December 31, 2014, will be released before the opening of the market on Thursday, February 26, 2015. MiMedx will host a live broadcast of its fourth quarter and year-end conference call on Thursday, February 26, 2015, at 10:30 a.m. EST. A listen-only simulcast of the MiMedx conference call will be available online at the Company's website, www.mimedx.com. A 30-day online replay will be available approximately one hour following the conclusion of the live broadcast. The replay can also be found on the Company's website at www.mimedx.com.
MDXG: 8.65 (+0.23)
Organogenesis Announces MiMedx Has Dismissed its Frivolous Lawsuit
PR Newswire - Wed Feb 04, 7:00AM CST
Organogenesis Inc., a world leading regenerative medicine company, announced today that MiMedx Group, Inc. (NASDAQ: MDXG) has dismissed its lawsuit against the company, a mere month after it was announced.
MDXG: 8.65 (+0.23)
The Shuman Law Firm Investigates MiMedx Group, Inc.
Business Wire - Tue Feb 03, 7:00PM CST
The Shuman Law Firm announces that it is investigating potential claims against certain officers and directors of MiMedx Group, Inc. ("MiMedx" or the "Company"
(Nasdaq: MDXG). MiMedx is a Georgia-based company that designs, manufactures, and markets products and tissue processing services in the United States. MDXG: 8.65 (+0.23)
INVESTOR ALERT: Investigation on Behalf of Investors of MiMedx Group, Inc. Announced by Law Offices of Howard G. Smith
Business Wire - Tue Feb 03, 5:32PM CST
Law Offices of Howard G. Smith announces that it is investigating potential claims on behalf of investors of MiMedx Group, Inc. ("MiMedx Group" or the "Company"
(NASDAQ:MDXG) concerning possible violations of federal securities laws. MiMedx Group designs, manufactures and markets tissue processing products and services in the United States. Long-term shareholders of MiMedx Group are encouraged to contact the firm for more information MDXG: 8.65 (+0.23)
MiMedx Withdraws Complaint Against Organogenesis Without Prejudice To Focus On Investigation
PR Newswire - Tue Feb 03, 8:00AM CST
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced that it has voluntarily withdrawn its tortious interference lawsuit against Organogenesis, Inc., without prejudice. MiMedx has expressly reserved all of its rights and remedies to pursue any and all claims against Organogenesis in the future, including those that were brought in the Company's original complaint.
MDXG: 8.65 (+0.23)
MIMEDX GROUP, INC. FRAUD ALERT -- Andrews & Springer LLC Announces That a Securities Fraud Class Action Has Been Filed by a Law Firm Against MiMedx Group, Inc. - MDXG
GlobeNewswire - Mon Jan 26, 7:23AM CST
Andrews & Springer LLC, a boutique securities class action law firm focused on representing shareholders nationwide, announced today that a securities fraud class action lawsuit has been filed on behalf of investors of MiMedx Group, Inc. (Nasdaq:MDXG) ("MiMedx Group" or the "Company"
for possible corporate misconduct and violations of securities laws. MDXG: 8.65 (+0.23)
Robbins Arroyo LLP Is Investigating the Officers and Directors of MiMedx Group, Inc. (MDXG) on Behalf of Shareholders
PR Newswire - Thu Jan 22, 12:45PM CST
Shareholder rights law firm Robbins Arroyo LLP is investigating whether certain officers and directors of MiMedx Group, Inc. (NASDAQCM: MDXG) breached their fiduciary duties to shareholders. MiMedx designs, manufactures, and markets products and tissue processing services in the United States.
MDXG: 8.65 (+0.23)
Lifshitz & Miller Law Firm Announces Investigation of ChannelAdvisor Corp., eHealth, Inc., InvenSense, Inc., MiMedx Group, Inc., MWI Veterinary Supply, Inc. and Xoom Corporation
PR Newswire - Thu Jan 15, 1:36PM CST
ChannelAdvisor Corp.
MWIV: 189.72 (-0.17), ECOM: 9.69 (+0.63), INVN: 16.08 (+0.09), MDXG: 8.65 (+0.23), XOOM: 15.77 (+0.64), EHTH: 10.91 (-0.04)
MiMedx Announces over 30 National Account Contracts
PR Newswire - Mon Jan 12, 7:45AM CST
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today that the status of the Company's National Account contracts with Group Purchasing Organizations ("GPOs"
and Integrated Delivery Networks ("IDNs" represent in excess of 4,000 U.S hospitals under contract for MiMedx allografts. MDXG: 8.65 (+0.23)
MiMedx Exceeds Fourth Quarter And Full Year 2014 Revenue Forecasts
PR Newswire - Mon Jan 12, 7:15AM CST
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today its record results for the fourth quarter and full year 2014, and reaffirmed its previous guidance for 2015.
MDXG: 8.65 (+0.23)
Schubert Jonckheer & Kolbe LLP Launches Investigation into Alleged Breaches of Fiduciary Duty by MiMedx Group, Inc.'s Board and Officers
PR Newswire - Fri Jan 09, 10:00AM CST
Shareholder and consumer rights law firm Schubert Jonckheer & Kolbe LLP has launched an investigation into whether certain officers and directors of MiMedx Group, Inc. (NASDAQ: MDXG) breached their fiduciary duties to MiMedx and its shareholders.
MDXG: 8.65 (+0.23)
MiMedx Group, Inc. Investors Encouraged to Contact Securities Law Firm about Investigation into Allegations of Corporate Wrongdoing
PR Newswire - Thu Jan 08, 12:13PM CST
Securities lawyers at Dunnam & Dunnam are investigating allegations for MiMedx Group, Inc. shareholders (NASDAQ: MDXG). Concerned MDXG investors who purchased between February 26, 2014 and December 31, 2014 are encouraged to contact securities attorney Hamilton Lindley by clicking here.
MDXG: 8.65 (+0.23)
MiMedx's board announces increase of USD10m in stock repurchase plan
M2 - Wed Jan 07, 5:45AM CST
Regenerative medicine company MiMedx Group (NasdaqCM:MDXG) said on Tuesday that its board of directors has increased its share repurchase plan from USD10m to USD20m.
MDXG: 8.65 (+0.23)
Law Firm Kirby McInerney LLP Investigating Potential Claims on Behalf of MiMedx Group, Inc. Stockholders
Business Wire - Tue Jan 06, 5:58PM CST
Kirby McInerney LLP is investigating potential claims against the Board of Directors of MiMedx Group, Inc. ("MiMedx" or the "Company"
(Nasdaq:MDXG) concerning the government investigation into the Company's sales and marketing activities. MDXG: 8.65 (+0.23)
MiMedx Announces $10 Million Increase to Stock Repurchase Program
PR Newswire - Tue Jan 06, 10:35AM CST
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today its Board of Directors increased the Company's authorization for its share repurchase plan from $10,000,000 to $20,000,000. The $20,000,000 authorization announced today amends the $10,000,000 authorization approved in May 2014.
MDXG: 8.65 (+0.23)
Investor Alert: Investigation into MiMedx Group Inc. Announced by Holzer & Holzer, LLC
Business Wire - Tue Jan 06, 10:34AM CST
Holzer & Holzer, LLC is investigating whether MiMedx Group, Inc. ("MiMedx" or the "Company"
(NASDAQ: MDXG) and/or certain of its officers complied with the federal securities laws in making public statements regarding its business and operations. On December 31, 2014, MiMedx announced it received a subpoena from the Office of Inspector General of the Department of Health and Human Services relating primarily to a civil investigation into the Company's sales and marketing activities. The price of MiMedx stock has fallen dramatically following the announcement. MDXG: 8.65 (+0.23)
MiMedx - A Contrarian Viewpoint
Trader Junky - at Seeking Alpha - Tue Jan 06, 10:12AM CST
MDXG: 8.65 (+0.23)
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of MiMedx Group, Inc.
PR Newswire - Mon Jan 05, 3:25PM CST
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of MiMedx Group, Inc. ("MiMedx" or the "Company"
(NasdaqCM: MDXG -News). Such investors are advised to contact Peretz Bronstein or his investor relations coordinator Eitan Kimelman at info@bgandg.com or 212-697-6484. MDXG: 8.65 (+0.23)
Can MiMedx (MDXG) Double Despite FDA Investigation? - Video Blog
David Bartosiak - Zacks Investment Research - Mon Jan 05, 1:44PM CST
Momentum Strategist David Bartosiak discusses MiMedx (MDXG) and the FDA investigation.
MDXG: 8.65 (+0.23)
INVESTOR ALERT: Investigation of MiMedx Group, Inc. Announced by Glancy Binkow & Goldberg LLP
Business Wire - Mon Jan 05, 12:58PM CST
Glancy Binkow & Goldberg LLP announces that it is investigating potential claims on behalf of investors of MiMedx Group, Inc. ("MiMedx Group" or the "Company"
(NASDAQ:MDXG) concerning possible violations of federal securities laws. The investigation is focused on the Company's business and operations. MDXG: 8.65 (+0.23)
